MOXD1 and neuroblastoma: We analyzed microarray-derived expression data acquired from dissected sympathetic ganglia from hyperplastic lesions at week 2 and tumor tissue at week 6 from the Tyrosine hydroxylase (TH)–MYCN–driven neuroblastoma mouse model presented by De Wyn et al. (41) and found that MOXD1 expression steadily decreases with tumor progression (Fig. 3A).